ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) received a near-term payment from SynBioTx under the license and collaboration agreement for IMM2510 and IMM27M, according to a Wednesday filing with the Hong Kong bourse.
The company has received $15 million in upfront and near-term payments. It expects to receive a further $35 million in near-term payments in the future.
In August, the pharmaceutical gave SynBioTx an exclusive license to research, develop, and commercialize IMM2510 and IMM27M.
Price (HKD): $3.30, Change: $-0.25, Percent Change: -7.04%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments